Back to search results

Early Psychiatric Referral for Sarcoma Patients

This study is looking at how helpful it is for people with sarcoma (a type of cancer that grows in bones and soft tissues) to get mental health support early in their treatment. The main thing being tested is a referral to the Memorial Sloan-Kettering Cancer Center (MSK) Department of Psychiatry and Behavioral Sciences. Researchers want to see if this early referral can help with depression, anxiety, recovery after surgery, and overall satisfaction. You may be able to join if you are at least 18 years old, have a new diagnosis of bone or soft tissue sarcoma, are having surgery at MSK, and haven't had previous sarcoma treatment. The study aims to enroll 60 participants. The main goal is to see how many people complete their scheduled study visits over two years.

Study design
This is an interventional study with an unclear status, aiming to enroll 60 participants. It is not specified if it is randomized or blinded.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for two years to measure the number who complete scheduled study visits.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06129903

Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma

Recruiting
NAAges 18+InterventionalPrevention
Memorial Sloan Kettering Cancer Center
~60 participants
Updated 2026-05-15 on ClinicalTrials.gov
What's tested:referral to the Memorial Sloan-Kettering Cancer Center (MSK) Department of Psychiatry and Behavioral Sciences.

At a glance

Recruiting sites
7 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The number of participants who complete scheduled study visits
Measured over 2 years

Conditions

Sarcoma
Bone Sarcoma
Soft Tissue Sarcoma

Explore related trials

Bone SarcomaSoft Tissue Sarcoma

Where it's being run

8 sites across 3 states
New York4
New Jersey3
Texas1

Study leadership

  • Meredith Bartelstein, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Meredith Bartelstein, MD
[email protected]
212-639-8684
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥18 years
Tissue diagnosis of primary bone or soft tissue sarcoma
Presenting to the Orthopaedic Surgery Service
Treatment plan includes surgery at MSK for treatment of the primary sarcoma
No previous treatment for sarcoma
Proficient in English
As determined by use of the Census-LEP question
The patient's response to the question: "How well do you speak English?" must be "very-well" for inclusion. Additionally, English must be identified as the patient's preferred language for discussing healthcare.

Exclusion

Significant psychiatric disturbance determined from self-report and/or chart review, sufficient, in the investigator's judgment, to preclude participation in the study" (e.g., underlying severe mental illness, h/o suicide attempts, or h/o psychiatric admissions) Clinical concern at the time of randomization of mental health urgency or emergency requiring evaluation; urgency and emergency will be defined as moderate or high scores, respectively, on the CSSR-S or according to the judgment of the orthopaedic physician evaluating the patient
Note: investigators considered exclusion of patients with no or mild symptoms of anxiety and depression, however due to risk of new symptoms arising during the course of treatment, risk of underreporting, risk of under detection, and given prior data on the high prevalence of symptoms, we elected to include all patients in this pilot study.

What this trial measures

  • The number of participants who complete scheduled study visits2 years

    The study will evaluate the feasibility of conducting a randomized clinical trial studying the impact of early referral to psychiatry (versus no referral) on depression and anxiety symptoms in patients with musculoskeletal sarcoma by examining the rates of eligibility, acceptance, uptake rate, and adherence.